Gene Sequencing, Genetics and Immune Response

Takeda grows in gene therapies again with $2bn Code Bio deal

pharmaphorum

FEBRUARY 23, 2022

Takeda has forged another alliance as it continues a push into gene therapy, agreeing a deal worth up to $2 billion with Code Biotherapeutics for opt-in rights to four candidates for rare diseases. The deal is mostly back-loaded, with “double-digit million” dollars in upfront payment, research funding and milestone payments.

Gene Therapy

Gene Therapy Gene Gene Sequencing Immune Response

Zynteglo halt re-ignites viral vector safety concerns; analysts

pharmaphorum

FEBRUARY 22, 2021

If a causal link is shown, it could have “significant ramifications” on the use of lentiviral vectors, a type of self-inactivating virus that underpins both approved cell therapies like Novartis’ CAR-T Kymriah as well as a host of experimental therapies that involve genetic manipulation of cells. million in Europe.

Gene Therapy

Gene Therapy Gene Gene Sequencing Gene Expression

Clinical Research Informer

Takeda grows in gene therapies again with $2bn Code Bio deal

Zynteglo halt re-ignites viral vector safety concerns; analysts

Webinars

Stay Connected